ATOS
Atossa Therapeutics, Inc.
1W: +7.2%
1M: +21.5%
3M: +652.0%
YTD: -43.2%
1Y: +622.5%
3Y: +726.1%
5Y: +84.5%
$5.33
+0.20 (+3.90%)
After Hours: $5.87 (+0.54, +10.13%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$45.9M
52W Range3.76-19.35
Volume152,166
Avg Volume145,594
Beta1.49
Dividend—
Analyst Ratings
Company Info
CEOSteven C. Quay
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2012-11-08
Websiteatossatherapeutics.com
107 Spring Street
Seattle, WA 98104
US
Seattle, WA 98104
US
206 588 0256
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Latest News
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $6.33 Consensus PT from Brokerages
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| QUAY STEVEN C | A-Award | 331,674 | — | 2026-01-20 |
| QUAY STEVEN C | A-Award | 325,203 | — | 2026-01-20 |
| QUAY STEVEN C | A-Award | 950,000 | $0.60 | 2026-01-20 |
| Daniel Mark James | A-Award | 578,000 | $1.03 | 2025-10-14 |
| Daniel Mark James | 0 | — | 2025-10-14 |